How do I buy Iovance Biotherapeutics, Inc. Common Stock (IOVA) stock?

Buying Iovance Biotherapeutics, Inc. Common Stock (IOVA) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "IOVA", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy IOVA by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if IOVA is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Iovance Biotherapeutics, Inc. Common Stock (IOVA) Stock

Q: What is the minimum investment for IOVA on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Iovance Biotherapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · IOVA

Trade IOVA

Key stats

Market cap: $3.74B
Price / Earnings ratio: -17.0x
EPS (TTM): -$0.50
Volume: Loading
52-week high: $15.37
52-week low: $2.08

Source: third-party data provider, as of November 13, 2026

Compare with IOVA

Technical indicators

RSI 14: 33.49
MACD 12/26/9: -1.27
EMA 9 of MACD: -0.76
MACD histogram: -0.50
SMA 50: $11.37; Price below SMA 50
EMA 50: $10.55; Price below EMA 50
SMA 200: $6.06; Price above SMA 200
EMA 200: $6.82; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 9 analyst ratings

Strong Sell0

Sell0

Hold2

Buy7

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

316M209M104M0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

1B723M362M0

Revenue to Profit

2025

$263.5M

Revenue

$0.0

Cost of revenue

$90.3M

Gross profit

$0.0

Operating expenses

$-391.0M

Net income

Earnings

No data available

Source: third-party data provider

About Iovance Biotherapeutics, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees975

CEODr. Frederick G. Vogt Esq., J.D., Ph.D.

IPO DateOct 15, 2010

HeadquartersSan Carlos, CA

Key Executives

Name	Title	Year Born
Dr. Frederick G. Vogt Esq., J.D., Ph.D.	Interim CEO, President, General Counsel, Corporate Secretary & Director	1974
Ms. Corleen M. Roche	Chief Financial Officer	1966
Dr. Igor P. Bilinsky Ph.D.	Chief Operating Officer	1973
Dr. Raj K. Puri M.D., Ph.D.	Chief Regulatory Officer	1956
Mr. Daniel G. Kirby	Chief Commercial Officer	1972
Ms. Sara Pellegrino	Senior Vice President of Investor Relations & Corporate Communications	—
Ms. Tracy Winton	Executive Vice President of Human Resources	—
Mr. Howard B. Johnson M.B.A.	Chief Business Officer	1960
Mr. Kevin Smyth	Executive Vice President of Quality	—
Dr. Brian Gastman M.D.	Executive Vice President of Translational Medicine & Research	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-4.4	+8.6
2022	-12.8	-7.7	+7.9	-11.5	-58.8	+73.0	+1.6	-3.6	-12.4	+0.0	-31.7	-0.3
2023	+30.3	-7.8	-16.3	-10.2	+35.9	-19.4	+2.3	-16.0	-26.0	-13.8	+56.8	+29.9
2024	-4.6	+97.4	-11.7	-17.0	-29.0	-4.2	+8.3	+42.9	-13.5	+11.7	-16.7	-18.4
2025	-24.9	-24.8	-17.6	+10.5	-47.4	-2.3	+47.7	-16.8	-0.9	-10.9	+26.7	+22.4
2026	+1.2	+47.9	-7.4	-2.6	+20.6	+5.1	+2.5	+89.1	+79.0	-40.4	+0.9

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Iovance Biotherapeutics, Inc. Common Stock (IOVA) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "IOVA", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy IOVA by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Iovance Biotherapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Iovance Biotherapeutics, Inc. Common Stock (IOVA) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track IOVA's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Iovance Biotherapeutics, Inc. Common Stock (IOVA) Stock

Key stats

Compare with IOVA

Recent news

CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?

CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?

Iovance Gears Up to Report Q3 Earnings: Here's What to Expect

Iovance Gears Up to Report Q3 Earnings: Here's What to Expect

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?

CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?

Iovance Gears Up to Report Q3 Earnings: Here's What to Expect

Iovance Gears Up to Report Q3 Earnings: Here's What to Expect

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next

SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3

SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3

Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus

Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus

Iovance's Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing

Iovance's Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing

Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist

Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist

IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall?

IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall?

Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

About Iovance Biotherapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade